On Wednesday, Maven announced our $45 Million Series C—one of the largest funding rounds in the history of women’s and family healthcare. We also introduced our latest product innovation, Maven Wallet, to manage an employer’s fertility, egg freezing, adoption, or surrogacy benefits and an employee’s receipts and reimbursement process. We’re thrilled by all of the support and congratulatory words we’ve received, and humbled by the media attention. Before the week ends, we’re excited to share just a few media highlights.
Forbes
Maven raises a $45 Million Series C—one of the largest funding rounds for a female-led women’s healthcare company
“If you don’t help women and babies at the start of life, how do you build a functional healthcare system? It’s not just a niche, it’s actually the core,” Maven’s Founder & CEO, Kate Ryder, told Forbes in their feature on our fundraise announcement and what it means for the future of women’s and family health.
Bloomberg
Maven is expanding to help employees use their fertility benefits
“This year, the company introduced Maven Wallet to manage an employer’s fertility or adoption benefits by allowing workers to use the platform to pay for services that can be costly.” Bloomberg highlighted our latest product, Maven Wallet, which helps employers manage fertility, egg freezing, adoption, or surrogacy benefits, and facilitates reimbursements for employees while guiding them to the highest-quality providers and clinics to lower costs and improve outcomes.
TechCrunch
Expanding its women’s health benefits offerings for employers, Maven raises $45 million
“With its virtual care and services, Maven is changing how global employers support working families by focusing on improving maternal outcomes, reducing medical costs, retaining more women in the workplace, and ultimately supporting every pathway to parenthood,” Tom Mawhinney, lead investor from Icon Ventures, shared in TechCrunch’s feature on our Series C.
FierceHealthcare
Maven scores $45M series C with 23andMe’s Wojcicki, A-list actors as investors
“Only a few women’s health startups have made it to a series C round,” FierceHealthcare called out in their feature on Maven’s announcement, pointing to the importance of our “end-to-end support in areas including preconception, egg freezing, IVF/IUI, adoption, surrogacy, pregnancy, postpartum, early pediatrics, return-to-work, and breast milk shipping”. Maven was named to FierceHealthcare’s Fierce 15 2020 list in January.
%20(1).png)
.svg)
.png)
%20(1).jpeg)
.jpeg)
